|
Synonyms: IGE25 | olizumab | R03DX05 | RG-3648 | rhumab-E25 | Xolair®
omalizumab is an approved drug (FDA (2003), EMA (2005))
Compound class:
Antibody
Comment: Omalizumab is an anti-IgE monoclonal antibody that was desigend to target IgE-mediated allergic inflammatory responses.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis reveals that omalizumab is clone e25 in patent US5994511 [8]. Biosimilars: The EMA approved Celltrion's biosimilar Omlyclo® in May 2024, to treat allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in patients for whom other therapy options have failed to control symptoms. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: omalizumab |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2003), EMA (2005)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8039 | omalizumab |
| Synonyms |
| IGE25 | olizumab | R03DX05 | RG-3648 | rhumab-E25 | Xolair® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 77 |
| Other databases | |
| GtoPdb PubChem SID | 178103472 |
| PubChem SID | 178103472 |
| Search PubMed clinical trials | omalizumab |
| Search PubMed titles | omalizumab |
| Search PubMed titles/abstracts | omalizumab |
| Wikipedia | Omalizumab |
